Can a new drug slow Alzheimer's? major study launches
NCT ID NCT06566170
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether adding the drug donanemab to standard care helps people with early Alzheimer's stay independent longer. Researchers will follow about 6,250 participants for over 5 years, tracking when they need more help with daily tasks. The goal is to see if donanemab can slow the disease's progression in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rehabilitation & Neurological Services
RECRUITINGHuntsville, Alabama, 35805-4046, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Could your heart hold the key to Alzheimer's prevention?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a Voice-Based app map healthy brain aging across 80 years?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can brain scans and gut bacteria reveal Alzheimer's secrets?